|  |
| --- |
| THE UNIVERSITY OF JORDAN, SCHOOL OF PHARMACY, AMMAN 11942, JORDAN |
| E-mail MOH.SALEH@JU.EDU.JOEffective date: MAY,26,2021 |

Mohammad I Saleh

|  |
| --- |
| **SUMMARY** |
|  | Respected and dedicated associate professor with experience in teaching;biopharmaceutics and clinical pharmacokinetics; clinical and field training;academic administration; and accreditation of professional degree programs. |
| **PERSONAL INFORMATION** |
|  | Address: School of Pharmacy, The University of Jordan, Amman, 11942, Jordan Phone: +96265355000 ext. 23347, Mobile phone: +962798301950Email: moh.saleh@ju.edu.jo |
| **EDUCATION** |
|  | **2007-2012,***PhD in Pharmacy*Thesis title: “**Population pharmacokinetic/pharmacodynamic analysis of erythropoiesis kinetics**”University of Iowa1. Cumulative GPA of 4.05 out of 4.00

**1999-2004,***BSc in Pharmacy*The University of Jordan1. Cumulative GPA of 3.92 with honor degree (rank = 1st)
 |
| **Work experience** |
|  | **Dec, 2020-Now,**Vice Dean for quality and development affairsCollege of Pharmacy, The University of Jordan**Sep, 2016-Dec, 2020,**Head of Department of Biopharmaceutics & Clinical Pharmacy College of Pharmacy, The University of Jordan**Sep, 2016- Dec, 2020,**Director of MSc. in Clinical Pharmacy programCollege of Pharmacy, The University of Jordan**Sep, 2016- Dec, 2020,**Director of Doctor of PharmacyCollege of Pharmacy, The University of Jordan**Sep, 2014-Aug, 2016,**Associate Dean for Training Affairs College of Pharmacy, The University of Jordan**Feb, 2020-Now,**Professor of biopharmaceutics and clinical pharmacokineticsCollege of Pharmacy, The University of Jordan**Feb, 2016-Feb, 2020,** Associate professor of biopharmaceutics and clinical pharmacokineticsCollege of Pharmacy, The University of Jordan**Feb, 2012-Feb, 2016,** Assistant professor of biopharmaceutics and clinical pharmacokineticsCollege of Pharmacy, The University of Jordan**May, 2011-Sep, 2011,** Pharmacokinetics intern in the department of Clinical pharmacology Takeda Oncology, Cambridge, Massachusetts, USA**May, 2009-Aug, 2009,** Pharmacokinetics intern in the department of Clinical pharmacology/ diabetes pipelineMerck & Co Inc , West Point, Pennsylvania, USA**Dec, 2006-Jan, 2012,** Research assistantCollege of Pharmacy*,*The University of Iowa**Oct, 2005- Oct, 2006,**Teaching assistantCollege of Pharmacy, The University of Jordan**Jul, 2004-Aug, 2005,**Formulator in the research and development departmentDar Al Dawa® pharmaceutical company, Jordan |
| **professional organizations and KEY COMMITTEES** |
|  | * Accreditation Council for Pharmacy Education (ACPE) certification steering committee (School of pharmacy/ The University of Jordan)
* American association of pharmaceutical sciences (AAPS)
* Jordan Pharmaceutical Association
* Bioequivalence committee in Jordanian Food and Drug Administration
* Topical preparations committee in Jordanian Food and Drug Administration
 |
|  |
| **TEACHING EXPERIENCE** |
|  | * Biopharmaceutics
* Pharmacokinetics
* Case studies in pharmacokinetics
* Advanced biopharmaceutics and pharmacokinetics (for master students)
* Clinical research methods and statistics (for master students)
* Clinical Pharmacokinetics (for PharmD students)
* Clinical pharmacokinetics clerkship
* Clinical pharmacokinetics (for master students)
* Pharmacology I
* Pharmacology II
* Pharmacology for paramedics
* Medical terminology
* Surgery clerkship
* Nephrology clerkship
* Oncology clerkship
 |
| **Masters student supervision** |
|  | * Co-Supervisor of MSc. Project of student Hiba Ibrahim Musleh Al Fahmawi titled: “The impact of clinical pharmacist in the identification and management of treatment- related problems in the surgery ward”. Passed August, 2020
* Supervisor of MSc. Project of student Dana Helal titled: “Pharmacodynamic modeling of longitudinal change in glycemic response to rosiglitazone therapy in type 2 diabetic patients”. Passed July, 2019
* Co-Supervisor of MSc. Project of student Mohannad Hussein Fayez abu dobay titled: “Pharmacodynamic modeling of Glibenclamide-induced changes in hemoglobin A1C in type2 diabetic patients”. Passed May, 2019
* Co-Supervisor of MSc. Project of student Anwar Abdel Qader Hindi Jaffal titled: “Disease progression model to describe longitudinal change in Hemoglobin A1C in response to Gliclazide therapy in type2 Diabetic patients”. Passed May, 2019
* Supervisor of MSc. Project of student Mohammad Obaidat titled: “Disease progression model to describe longitudinal change in hemoglobin A1C in response to glimepiride therapy in type 2 diabetic patients”. Passed April, 2019
* Co-Supervisor of MSc. Project of student Marwa Ghareeb titled: “A cross-sectional study of cathepsin s and adipolin plasma levels and their correlations with a set of clinical parameters in normoglycemic and hyperglycemic patients with metabolic syndrome in Jordan”. Passed December, 2018
* Co-Supervisor of MSc. Project of student Safa’a Ali Al-Qudah titled: “A cross sectional Study of Nesfatin and Lipopolysaccharide Binding Protein Plasma Levels and their Correlations with a set of Clinical Parameters in Normoglycemic and Hyperglycemic Patients with Metabolic Syndrome in Jordan”. Passed May 29th, 2018
* Co-Supervisor of MSc. Project of student Govand Yassin Saber titled: “Study of the correlation between plasma levels of irisin and fibroblast growth factor 1 (FGF1) and their correlations with a set of clinical parameter in normoglycemic and hyperglycemic patients with metabolic syndrome in jordan: a cross-sectional study”. Passed April 26th, 2018
* Co-Supervisor of MSc. Project of student Sereen Helmi Shoubash titled: “Cardiac adverse events of direct acting antivirals in chronic hepatitis C patients”. Passed May 3rd, 2018
* Supervisor of MSc. Project of student Islam Mohammad Al-Ashram titled: “Evaluation of the renal safety of direct acting antivirals in chronic hepatitis C patients”. Passed May 3rd, 2018
* Supervisor of MSc. Project of student Suhad Bani Melhem titled: “Patients characteristics associated with virological response in patients with chronic hepatitis C infection receiving peginterferon alfa-2a and ribavirin combination”. Passed April 27th, 2017
* Supervisor of MSc. Project of student Nagham Nafiz Hindi titled: “Patient characteristics associated with chronic hepatitis C induced neutropenia”. Passed April 17th, 2017
* Supervisor of MSc. Project of student Ghaida Tayseer Nsour titled: “Patient characteristics associated with chronic hepatitis C induced thrombocytopenia”. Passed March 15th, 2017
 |
| **PROGRAMMING SKILLS** |
|  | * Monolix
* NONMEM
* R/S-plus
* MATLAB
* SAS
* WINBUGS
* Winnonlin
* Kinetica
* SPSS
* Fortran
* C++
 |
| **Publications** |
|  | 1. Al-Ghazawi, M., Saleh, M.I., Najib, O. et al. Population Pharmacokinetics of Ibrutinib in Healthy Adults. Eur J Drug Metab Pharmacokinet (2021). <https://doi.org/10.1007/s13318-021-00679-z>
2. Abdel Jalil, MH, Abdullah, N, Alsous, MM, Saleh, M, Abu‐Hammour, K. **A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population**. Br J Clin Pharmacol. 2020; 86: 1267– 1280
3. Saleh, Mohammad I. **A Bayesian approach for population pharmacokinetic modeling of pegylated interferon α 2a in hepatitis C patients.** Clinical Pharmacokinetics 56:11 (2017): 1369-1379
4. Alshogran, O.Y., L.S. Magarbeh, K.H. Alzoubi, M.I. Saleh and O.F. Khabour, **Evaluation of the impact of waterpipe tobacco smoke exposure on the activity and expression of rat hepatic CYP450: a pharmacokinetic study**. Inhal Toxicol, 2018. 30(13-14): p. 519-526.
5. Kasabri, V., M.I. Al-ghareeb, M.I. Saleh, M. Suyyagh, L. Halaseh, I. Al-Sarraf and S. AlAlawi, **Proportional correlates of adipolin and cathepsin S in metabolic syndrome patients with and without prediabetes**. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019.
6. Saber, G.Y., V. Kasabri, M.I. Saleh, M. Suyagh, L. Halaseh, R. Jaber, H. Abu-Hassan and S. Alalawi, **Increased irisin versus reduced fibroblast growth factor1 (FGF1) in relation to adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes**. Hormone molecular biology and clinical investigation, 2019. 38(1).
7. Alkhalidi, B.A., H.S. AlKhatib, M. Saleh, S. Hamed, Y. Bustanji, N. Al Bujuq, N. Najib, S. Torrado-Susana and A.S. Sallam, **Clarithromycin laurate salt: physicochemical properties and pharmacokinetics after oral administration in humans**. Pharm Dev Technol, 2019. 24(5): p. 607-615.
8. Saleh, M.I. and S. Bani Melhim, **A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection**. J Chemother, 2019: p. 1-10.
9. Saleh, M., et al., **Bayesian population pharmacokinetic modeling of eltrombopag in chronic hepatitis C patients**. European Journal of Drug Metabolism and Pharmacokinetics, 2018.
10. Saleh, M. and N. Hindi, **A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection**. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018: p. 1-11.
11. Al-Qudah SaA, Kasabri V, Saleh MI, Suyagh M, AlAlawi S, and Yasin N. **Cross-sectional correlates of nesfatin and lipopolysaccharide binding protein in metabolic syndrome patients with and without prediabetes.** Horm Mol Biol Clin Investig 2018.
12. Alsous M, Hamdan I, Saleh M, McElnay J, Horne R, and Masri A. **Predictors of nonadherence in children and adolescents with epilepsy: A multimethod assessment approach**. Epilepsy Behav 2018; 85: 205-11.
13. Hindi, N.N. and M.I. Saleh, **Patient characteristics associated with peglyated interferon alfa‐2a induced neutropenia in chronic hepatitis C patients.** Clinical and Experimental Pharmacology and Physiology, 2018.
14. Zalloum N, Saleh MI, Al Haj M, Balbisi M, and Al-Ghazawi M. **Population pharmacokinetics of vancomycin in Jordanian patients.** Tropical Journal of Pharmaceutical Research 2018; 17(2): 351-358.
15. Saleh, Mohammad I. **Clinical predictors associated with warfarin sensitivity.** American journal of therapeutics 23:6 (2016): e1690-e1694.
16. Alzubiedi, Sameh, and Mohammad I. Saleh. **Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans.** Journal of cardiovascular pharmacology 67:1 (2016): 86-92.
17. Alzubiedi, Sameh, and Mohammad I. Saleh. **Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus Infection.** American journal of therapeutics (2015).
18. Saleh, Mohammad I., et al. **Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.** Clinical and Experimental Pharmacology and Physiology 42:10 (2015): 1030-1035.
19. Saleh M. I**. Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine**. European Review for Medical and Pharmacological Sciences. 2014; 18: 3935-3942.
20. Saleh, M.I., **Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence**. Pharmacopsychiatry, 2014. 47(7): p. 251-8.
21. Saleh MI, Alzubiedi S. **Dosage Individualization of Warfarin Using Artificial Neural Networks.** Molecular diagnosis & therapy. 2014.
22. Saleh, M.I., et al., **Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin.** Am J Physiol Regul Integr Comp Physiol, 2013.
23. Mock, D.M., et al., **Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [14C]cyanate: validation of a model to study human physiology and disease.** Transfusion, 2012. **52**(5): p. 963-73.
24. Mohammad Saleh, John Widness, and Peter Veng-Pedersen.**Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep.** Biopharm Drug Dispos, 2011.
25. Andrew Osei-Bimpong, Mohammad Saleh, Martha Sola-Visner, John Widness, and Peter Veng-Pedersen. **Correction for Effect of Cold Storage on Immature Platelet Fraction.** J Clin Lab Anal. Nov 2010;24(6):431-433
26. Demet Nalbant, Mohammad Saleh, Frederic Goldman, John Widness, and Peter Veng-Pedersen. **Evidence of receptor-mediated elimination of erythropoietin by analysis of Epo receptor mRNA expression in bone marrow and erythropoietin clearance during anemia.** J Pharmacol Exp Ther. May 2010;333(2):528-532.
 |
| **POSTER PRESENTATION** |
|  | * The third international conference of the Faculty of Pharmacy/ The University of Jordan 2012
* Mohammad I Saleh, Modeling longitudinal changes in opiate addiction status after a short-term stabilization with buprenorphine , The 15th Scientific Congress of the Jordanian Pharmacists Association: “Pharmacy Perspectives” An Evolving Role in Community Health, April 3rd-5th, 2014
* Sameh Al-Zubiedi, Mohammad Saleh, Pharmacogenetic-guided warfarin dosing algorithm in African American, Pharmacology 2014 (British Pharmacological Society), 16-18 December, 2014, Queen Elizabeth II Conference Centre, London
* Mohammad I. Saleh, Sameh Alzubiedi, Warfarin dosing algorithm using artificial neural networks, Faculty of Pharmacy Open day, April 29th 2015.
* N Gupta, M Saleh, K Venkatakrishnan, Switch from BSA-based dosing to fixed dosing for the investigational drug ixazomib citrate (IC): application of modeling and simulation to influence posology decisions in oncology drug development, Clinical Pharmacology & Therapeutics (2012)
 |
| **RESEARCH COLLABORATION** |
|  | * **Development of disease progression model that describes HbA1C change in diabetic patients.** Dr Saleh concluded a data sharing agreement with GlaxoSmithKline (GlaxoSmithKline Research and Development Ltd, with offices at 980 Great West Road, Brentford, Middlesex, TW8 9GS) to get access to 6 clinical trials that explores the efficacy of several anti-diabetic medications in type 2 diabetic patients.
* **Optimized peg-interferon alpha-2a Treatment of Hepatitis C and Hepatitis B.** Dr Saleh concluded a data sharing agreement with Roche (F. Hoffman-La Roche Ltd located at Grenzacherstrasse 124, CH-4070 Basel, Switzerland and its subsidiaries) to get access to 6 clinical trials that explores the efficacy of peg-interferon alpha-2a in the treatment of Hepatitis B or Hepatitis C infections
* **Optimized Eltrombopag Treatment of Hepatitis C virus-related thrombocytopenia.** Dr Saleh concluded a data sharing agreement with GlaxoSmithKline (GlaxoSmithKline Research and Development Ltd, with offices at 980 Great West Road, Brentford, Middlesex, TW8 9GS) to get access to 2 clinical trials that explores the efficacy of eltrombopag in the treatment of Patients with Hepatitis C virus-related thrombocytopenia.
* **Development of a disease progression model for opioid addiction status following buprenorphine therapy.** Dr Saleh obtained data from a clinical trial funded by National Institute on Drug Abuse to develop a model that describes longitudinal changes in buprenorphine treatment outcome for opioid dependence.
* **Development of a warfarin dosing algorithm using artificial neural networks.** Dr Saleh obtained data from PharmGKB (https://www.pharmgkb.org/) that was provided by International Warfarin Pharmacogenetics Consortium to develop a warfarin dosing algorithm using artificial neural networks.
 |
|

|  |
| --- |
| **References** |
|  | * Peter Veng-Pedersen, Ph.D., Professor of Pharmacokinetics

Division of Pharmaceutics and Experimental Therapeutics, College of Pharmacy, The University of Iowa, Iowa City, IA  52242Phone: (319) 335-8792;  Fax: (319) 335-9349Email: veng@uiowa.edu* Abla Albsoul-Younes, Ph.D.

Dean of School of Pharmacy (2016-2020), The University of JordanSchool of Pharmacy, University of Jordan Phone (office): 00962-65355000 Ext. 23349 or 23294, Phone (mobile): 00962-795652216Email: ablabsou@ju.edu.jo* Rula M. Darwish, Ph.D.

Dean of School of Pharmacy (2014-2016), The University of JordanSchool of Pharmacy, University of Jordan Phone (office): 00962-65355000 Ext. 23327, Phone (mobile): 00962-795558089Email: rulad@ju.edu.jo |

 |